Dilaudid (hydromorphone hydrochloride) for Severe Pain Management

Dilaudid contains hydromorphone hydrochloride, a potent opioid agonist used to manage severe pain when other treatments are inadequate. It is available as an injection solution for intravenous, intramuscular, or subcutaneous use, and as oral tablets. Dilaudid requires careful dosing and monitoring due to risks of addiction, respiratory depression, and other serious side effects.

Dilaudid Injection and Tablets are prescribed for the management of pain severe enough to require opioid analgesics and for which alternative treatments are inadequate.

Limitations: Use is reserved for patients who have not tolerated, do not expect to tolerate, or have not achieved adequate analgesia from non-opioid or other analgesic therapies.

hydromorphone hydrochloride

Hydromorphone hydrochloride, the active ingredient in Dilaudid, is an opioid receptor agonist. It works by binding to opioid receptors in the central nervous system to alter the perception of and response to pain, providing potent analgesia.

General Dosing Principles

• Prescribe only by healthcare professionals knowledgeable about opioid use and risk mitigation.
• Use the lowest effective dose for the shortest duration to meet individual pain management goals.
• Adjust dose based on severity of pain, prior analgesic experience, patient response, and risk factors for misuse.
• Careful titration and monitoring for respiratory depression are critical, especially during treatment initiation and dose increases.
• Do not abruptly discontinue in physically dependent patients; taper gradually.

Dilaudid Injection (Parenteral)

• Intramuscular or Subcutaneous: start at 1 mg to 2 mg every 2 to 3 hours as needed.
• Intravenous: start at 0.2 mg to 1 mg every 2 to 3 hours, inject slowly over 2-3 minutes.
• Reduce starting dose to one-fourth to one-half usual dose in hepatic or renal impairment.

Dilaudid Tablets (Oral)

• Usual starting dose is 8 mg every 12 hours orally, individualized to clinical situation.
• In hepatic or renal impairment, start with one-fourth to one-half the usual dose.
• Doses may be titrated to adequate analgesia with acceptable side effects.
• Supplemental doses of 5-15% of total daily dose may be given every 2 hours as needed for breakthrough pain (for tablets).

• Significant respiratory depression
• Acute or severe bronchial asthma in unmonitored settings or without resuscitation equipment
• Known or suspected gastrointestinal obstruction including paralytic ileus
• Hypersensitivity to hydromorphone, hydromorphone salts, sodium metabisulfite, or any product components

Serious and Life-Threatening Risks

• Addiction, Abuse, and Misuse: Risk exists at any dose or duration. Assess patient risk before and during therapy. Carefully monitor for signs of addiction.
• Respiratory Depression: May be severe or fatal; greatest risk during initiation or dose increases. Use proper dosing and monitoring to reduce risk.
• Concomitant CNS Depressants: Using Dilaudid with benzodiazepines, other CNS depressants, or alcohol may cause profound sedation, respiratory depression, coma, or death. Reserve such combinations for patients without alternatives and monitor closely.
• Neonatal Opioid Withdrawal Syndrome: Prolonged opioid use during pregnancy may cause withdrawal in newborns. Management by neonatology experts recommended.
• Adrenal Insufficiency: May occur with opioid use over one month; treat with corticosteroids and taper opioid.
• Severe Hypotension: Monitor blood pressure; avoid in circulatory shock.
• Increased Intracranial Pressure or Impaired Consciousness: Avoid use; monitor for sedation and respiratory depression.
• Hypersensitivity and Allergic Reactions: Contains sodium metabisulfite, which may cause anaphylaxis or asthmatic reactions in sensitive individuals.

Common Adverse Reactions

• Lightheadedness, dizziness, sedation
• Nausea, vomiting
• Sweating, flushing
• Dysphoria or euphoria
• Dry mouth, pruritus (itching)

Less Common Reactions

• Cardiac: tachycardia, bradycardia, palpitations
• Eye: blurred vision, diplopia, miosis
• Gastrointestinal: constipation, ileus, diarrhea, abdominal pain
• General: weakness, fatigue, chills, peripheral edema
• Immune: hypersensitivity, anaphylaxis
• Nervous system: headache, tremor, syncope, convulsions, hyperalgesia
• Psychiatric: agitation, anxiety, depression, hallucination
• Respiratory: bronchospasm, laryngospasm
• Skin: rash, urticaria, hyperhidrosis

Serotonin syndrome and opioid-induced adrenal insufficiency have also been reported.

Key Drug Interactions

• Benzodiazepines and Other CNS Depressants: Additive sedation and respiratory depression risk. Use concomitantly only if no alternatives, minimize doses and duration, monitor closely.
• Serotonergic Drugs: Risk of serotonin syndrome; discontinue if suspected.
• Monoamine Oxidase Inhibitors (MAOIs): Use not recommended during or within 14 days of MAOI treatment; may cause opioid toxicity or serotonin syndrome.
• Mixed Agonist/Antagonist or Partial Agonist Opioids: May reduce Dilaudid’s analgesic effect or precipitate withdrawal; avoid concomitant use.
• Muscle Relaxants: May enhance neuromuscular blockage and respiratory depression; monitor and adjust doses.
• Diuretics: May reduce diuretic efficacy via antidiuretic hormone release; monitor and adjust dosage.
• Anticholinergic Drugs: Increase risk of urinary retention and severe constipation; monitor patients closely.

Pregnancy

Prolonged use during pregnancy may cause neonatal opioid withdrawal syndrome, which can be life-threatening if not treated properly. Advise pregnant women on risks and ensure neonatology expertise is available at delivery.

Animal studies have shown some fetal effects at doses multiples of human levels.

Lactation

Hydromorphone is present in breast milk at low levels. Monitor breastfed infants for excess sedation and respiratory depression. Withdrawal symptoms may occur in infants if maternal use stops.